Dr. Cecilia Yeung is a pathologist with subspecialty training in anatomic/clinical pathology, hematopathology, and molecular genetic pathology. In the past 10 years, Dr. Yeung has honed her clinical expertise in molecular diagnostics, hematopoietic neoplasms, and transplant pathology and studied genomic changes and gene expression in hematologic malignancies. She has developed research expertise in gene expression, DNA microarray profiling, and the correlation of pathology data including histology, immunohistochemistry, flow cytometry, cytogenetics and molecular testing. Dr. Yeung’s interest in molecular pathology has led her to pursue novel molecular diagnostic platforms in order to push the limits for faster, simpler, more accurate, and more cost-effective diagnostic tools.
Dr. Radich is a medical oncologist who specializes in the molecular genetics of leukemia. He focuses on response, resistance, and relapse in hematological malignancies. This includes prediction-based gene expression and mutation analyses on pre-therapy samples, or sensitive measures to detect minimal residual disease and predict relapse. His lab is especially keen on applying cutting edge methods to develop diagnostics of clinical utility and served as the U.S. and Canadian reference laboratory for several large phase 2 and 3 trials of imatinib, dasatinib, and nilotinib, and were involved in the establishment of the International Scale for BCR-ABL testing. Dr. Radich’s team studies how specific genetic variants influence treatment responses and outcomes, enhancing doctors’ abilities to choose the best treatments for individual patients.
Dr. Paulovich is a leader in proteomics, the study of proteins — the cell’s workhorse molecules. Due to a lack of tools, proteomics has lagged behind the study of genes, which provide the blueprints for proteins. And just as a blueprint can’t tell you everything about a finished house, our genetic blueprint only reveals part of the biological picture. By developing powerful protein-measuring tools, Dr. Paulovich helps to fill in this picture and open the door to treatments tailored to individual cancer patients.